Floatz logo

Repotrectinib

Non-Small Cell Lung Carcinoma

Bristol-Myers SquibbSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

1205 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Veliparib
AbbVie
Phase 3BBB

View all 50 →

Same molecule, other indications

Repotrectinib is also rated in:

hormone receptor-positive breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →
invasive lobular breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
ROS1 Gene RearrangementDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →